BioMarin Pharmaceuticals (BMRN)

• Market cap: $13B
• 1 day: -3.89%
• 5 days: -5.09%
• 1 month: -4.34%
• 3 months: 2.18%
• 6 months: -3.08%
• Year to date: 2.18%
• 1 year: -22.00%
• 5 years: -18.72%
• 10 years: -43.83%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.

Employees: 3,401

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

75% more funds holding in top 10

Funds holding in top 10: 4 [Q3] → 7 (+3) [Q4]

1.88% more ownership

Funds ownership: 94.32% [Q3] → 96.2% (+1.88%) [Q4]

10% more repeat investments, than reductions

Existing positions increased: 199 | Existing positions reduced: 181

10% more call options, than puts

Call options by funds: $141M | Put options by funds: $128M

4% less first-time investments, than exits

New positions opened: 87 | Existing positions closed: 91

4% less capital invested

Capital invested by funds: $12.6B [Q3] → $12.1B (-$567M) [Q4]

3% less funds holding

Funds holding: 544 [Q3] → 529 (-15) [Q4]

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $70 3% upside
• Avg. target: $95 40% upside
• High target: $126 85% upside

8 analyst ratings

• positive: 5 63%
• neutral: 3 38%
• negative: 0 0%

Oppenheimer Leland Gershell 39% 1-year accuracy 20 / 51 met price target	44% upside $98	Outperform Upgraded	24 Feb 2025
Scotiabank George Farmer 27% 1-year accuracy 6 / 22 met price target	18% upside $80	Sector Perform Maintained	20 Feb 2025
Citigroup David Lebovitz 69% 1-year accuracy 11 / 16 met price target	21% upside $82	Neutral Maintained	20 Feb 2025
RBC Capital Luca Issi 22% 1-year accuracy 12 / 55 met price target	3% upside $70	Sector Perform Reiterated	20 Feb 2025
Cantor Fitzgerald Olivia Brayer 68% 1-year accuracy 13 / 19 met price target	32% upside $90	Overweight Reiterated	20 Feb 2025